Surgical site infections (SSIs) remain a major clinical challenge, particularly due to bacterial adhesion and biofilm formation on suture materials. In this study, we developed a dual drug-eluting suture incorporating chlorhexidine (CHX) and dexamethasone (DEX), with lauric acid used as a binding agent to enhance drug adhesion. The exact composition of the system was CHX/DEX/Lauric Acid, designed to enable localized delivery of both therapeutic agents at the implantation site. Vicryl sutures were dip-coated and characterized by means of FTIR-ATR and HPLC to confirm drug incorporation and release. Mechanical integrity was preserved, with no significant difference in tensile strength between coated and uncoated sutures. Antimicrobial activity was confirmed against Gram-positive and -negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), in addition to the yeast Candida albicans. Cell viability assays demonstrated acceptable biocompatibility, with values exceeding 70%. These findings support the potential of dual-functionalized sutures to reduce SSIs and modulate inflammation, offering a promising strategy for improving postoperative outcomes.
Hernández-Ramírez et al. (Sat,) studied this question.